We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Tokai Pharmaceuticals Announces $35.5 Million Series E Financing

News   May 17, 2013

 
Tokai Pharmaceuticals Announces $35.5 Million Series E Financing
 
 
 

RELATED ARTICLES

Discontinuing Oral Immunotherapy for Peanut Allergy Reduces Its Protective Effects

News

A study has followed participants after oral immunotherapy (OIT) for peanut allergy have found that discontinuing OIT or continuing OIT at a reduced dose led to a decline in its protective effects.

READ MORE

Some Cancer Drugs Don’t Work by Hitting Their Targets

News

Some cancer drug candidates in clinical trials kill cancerous cells through off-target effects instead of by interacting with their intended molecular targets, according to new study findings.

READ MORE

Drug That Combats Memory Loss in Alzheimer's Enters Phase II Trials

News

A new drug may protect against memory loss, nerve damage and other symptoms of Alzheimer's disease. The drug called BPN14770 is now in Phase 2 clinical trials in patients with Alzheimer's and Fragile X syndrome.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE